Lower doses of recombinant porcine factor VIII maintain excellent haemostatic efficacy.

Martin, K; Kasthuri, R; Mooberry, M J; Chen, S-L; Key, N S; Ma, A D

Martin, K; Kasthuri, R; Mooberry, M J; Chen, S-L; Key, N S; Ma, A D.

Afiliação

Martin K; Department of Medicine, Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC, USA.
Kasthuri R; Department of Medicine, Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC, USA.
Mooberry MJ; Department of Medicine, Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC, USA.
Chen SL; Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Key NS; Department of Medicine, Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC, USA.
Ma AD; Department of Medicine, Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC, USA.

Haemophilia ; 22(6): e549-e551, 2016 Nov.

Article em En | MEDLINE | ID: mdl-27704655

Assuntos

Fator VIII/administração & dosagem; Hemofilia A/tratamento farmacológico; Hemostáticos/uso terapêutico; Idoso; Animais; Feminino; Hemofilia A/sangue; Hemostasia; Humanos; Masculino; Pessoa de Meia-Idade; Proteínas Recombinantes/administração & dosagem; Suínos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fator VIII / Hemostáticos / Hemofilia A Limite: Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google